Why ApoB May Be a Better Test Than Cholesterol

Two people can have the same cholesterol level but very different heart disease risk. A simple test may explain why.

Apolipoprotein B is the orange protein on the right side of the yellow cholesterol carrier. The Epoch Times/Shutterstock

For some people, a normal cholesterol reading doesn’t always mean there’s nothing to worry about. For about the price of a dinner out, a simple blood test can reveal a hidden layer of heart disease risk that standard cholesterol tests often miss.

Yet it isn’t part of routine cholesterol screenings, so most doctors do not order it.

The test measures apolipoprotein B (apoB), a protein that sits on every particle that carries cholesterol through the bloodstream. Unlike standard cholesterol tests, which measure how much cholesterol is circulating, an apoB test counts the actual number of those harmful particles.

“Two people can have the same [low-density lipoprotein] cholesterol level, but the one with more apoB-containing particles may be at higher cardiovascular risk,” said Yiyi Zhang, an assistant professor at Columbia University Medical Center and an author of a recent study on the blood marker.

Looking Beyond Cholesterol Levels

Standard cholesterol tests focus largely on low-density lipoprotein (LDL), the so-called bad cholesterol, along with high-density lipoprotein (HDL) cholesterol.

Higher levels of LDL cholesterol in the blood are linked to an increased risk of heart attacks and strokes, and for decades, clinicians have used LDL as their primary guide for treatment.

However, heart disease risk is not just about the amount of cholesterol present. It also depends on the number of cholesterol carriers.

That number matters because these particles are not all the same size. Smaller LDL particles can produce a typical LDL reading but a higher total number of harmful particles overall—a pattern associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD).

An apoB test closes that gap. Because each particle carries exactly one apoB protein attached to it, measuring apoB gives a direct count of how many harmful, or atherogenic, particles—those capable of burrowing into artery walls and depositing plaque—are circulating in the blood.

When apoB levels are higher than expected relative to your LDL levels, this mismatch is called “discordance,” Ciaran Kohli-Lynch, an assistant professor of preventive medicine at Northwestern University and a co-senior author of one of the studies, told The Epoch Times in an email. That means the cholesterol number may look acceptable even though the number of particles carrying it is higher than expected.

In these cases, low or normal cholesterol measures may look reassuring, but they can give a false sense of security.

More particles circulating in the blood means more opportunities for them to contribute to plaque buildup. Over time, these plaques eventually restrict blood flow and can lead to heart attacks or strokes.

Alternatively, having low or normal apoB levels—even in people with high LDL cholesterol—predicts a lower likelihood of plaque buildup and a lower risk of atherosclerosis.

“If you have a family history of early heart disease, obesity, or other metabolic risk factors, apoB may offer additional information beyond standard LDL cholesterol tests,” Zhang said. “In these individuals, cardiovascular risk may be underestimated if apoB is not measured.”

A More Precise Guide to Treatment

Beyond helping identify risks that might otherwise be missed, apoB can help doctors decide how aggressively to treat that risk, and a new study suggests that it does so more cost-effectively than current practice.

In a study published in JAMA Network, Kohli-Lynch and colleagues used a computer model simulating about 250,000 U.S. adults eligible for statins to compare three ways of guiding cholesterol-lowering treatment: by LDL cholesterol, non-HDL cholesterol, and apoB.

They found that using apoB to guide treatment decisions gave the greatest overall benefit. It led to more treatment intensification when needed, which in turn prevented more heart attacks and strokes. The apoB-guided approach also produced more years of life in good health than the other approaches.

The Blind Spot in Younger Adults

ApoB tests may be especially useful for assessing heart disease risks in younger adults.

Standard 10-year risk calculators often look reassuring at younger ages, largely because age carries so much weight in those models that a 35-year-old with genuinely elevated cardiovascular risk can easily appear low-risk on paper.

“That means some people may appear low risk in the short term even though their cholesterol-related risk is higher than it seems,” Zhang said. “ApoB may help pick up some of that risk.”

In another study published in JAMA Network Open, Zhang and colleagues followed more than 10,000 adults for roughly two decades, drawing on data from three large U.S. cohort studies. They examined how well different cholesterol markers predicted future heart attacks and strokes.

Higher apoB levels were associated with greater heart disease risk and strokes across all age groups. However, the marker was especially informative in younger adults ages 18 to 39, where the risk gap between high and low apoB levels was four times greater than in older adults. In younger adults, a one-standard-deviation increase in apoB was linked to a 53 percent higher risk of ASCVD, compared with a 13 percent higher risk in adults ages 40 and older.

“We found that apoB may be more informative in younger adults,” Zhang said. “If apoB is elevated in young adulthood, those extra particles may be contributing to atherosclerosis decades before a heart attack or stroke occurs.”

Adding apoB to standard risk equations modestly improved the ability to identify which younger adults would go on to develop cardiovascular disease, helping distinguish people who might otherwise look similar based on traditional cholesterol tests alone.

For patients, the findings suggest that a “normal” cholesterol result at a younger age may not always tell the full story and that in some cases, additional testing could help clarify long-term risk.

Why ApoB Isn’t Used More Widely–Yet

ApoB tests are relatively inexpensive—often about $60 through major lab providers—but they are still not part of routine cholesterol screening. One reason is practical: The test usually has to be ordered separately, rather than included in a standard lipid panel.

There is also the question of habit. For decades, clinicians have relied on LDL cholesterol to assess risk and guide treatment, and shifting to a different approach can take time, even as evidence continues to build.

That may be starting to change. Current U.S. guidelines still use LDL cholesterol thresholds of less than 100 mg/dL for borderline or intermediate risk, less than 70 mg/dL for high risk, and less than 55 mg/dL for people with very high-risk heart disease.

However, health organizations, including the American Heart Association, are increasingly emphasizing earlier intervention, and newer cardiovascular risk tools such as PREVENT are beginning to take a broader view of risk beyond LDL cholesterol alone.

LDL and non-HDL cholesterol still provide useful information, said Kohli-Lynch, but apoB is more directly tied to heart attack risk because it reflects the number of harmful cholesterol-carrying particles in the blood.

For some people—especially those with diabetes, fatty liver disease, or obesity—that added clarity helps doctors decide when to start treatment, before it turns into something harder to reverse.